Skip to Main Content

Paper Details

The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
J Pathol
120
2020
BC, PD-1, PD-L1, Patients, TIL, TILs, TNBC, breast cancer, eosin, hematologic, hematologic and solid tumor types, hematoxylin, immune cells, nab, negative breast cancer, paclitaxel, patient, patients, tumor-infiltrating lymphocytes
Author NameAffiliation
Paula I Gonzalez-EricssonVanderbilt University Medical Center
John Le QuesneLeicester Cancer Research Centre, University of Leicester
John Le QuesneUniversity of Cambridge
John M S BartlettOntario Institute for Cancer Research
John M S BartlettEdinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine
David L RimmYale School of Medicine
Justin M BalkoVanderbilt University Medical Center
Justin M BalkoVanderbilt University Medical Center
Justin M BalkoVanderbilt University Medical Center
Wei YangFudan University Shanghai Cancer Centre
Carlos A Casta??edaInstituto Nacional de Enfermedades Neoplasicas
Stephen M HewittCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Stephen M HewittCenter for Cancer Research, National Cancer Institute, National Institutes of Health
William F SymmansThe University of Texas, MD Anderson Cancer Center
David A MooreCRUK Lung Cancer Centre of Excellence, UCL Cancer Institute
Alexander J LazarThe University of Texas, MD Anderson Cancer Center
Matthew P GoetzMayo Clinic
Christos SotiriouInstitut Jules Bordet, Universite Libre de Bruxelles
Sunil R LakhaniThe University of Queensland, Centre for Clinical Research, Royal Brisbane and Women's Hospital
Sunil R LakhaniThe University of Queensland, Centre for Clinical Research, Royal Brisbane and Women's Hospital
Sandra Demaria
Melinda E SandersVanderbilt University Medical Center
Melinda E SandersVanderbilt University Medical Center
  • 1 - 23

Datasets